Hepatitis C: When high drug prices preclude patient benefit

Hagop M. Kantarjian; Shilpa Paul

doi:10.1002/cncr.31292

Hepatitis C: When high drug prices preclude patient benefit

Hagop M. Kantarjian, Shilpa Paul

Leukemia

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	1644-1646
Number of pages	3
Journal	Cancer
Volume	124
Issue number	8
DOIs	https://doi.org/10.1002/cncr.31292
State	Published - Apr 15 2018

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/cncr.31292

Cite this

@article{a36da0a269924cd797adc6abb5d41d38,

title = "Hepatitis C: When high drug prices preclude patient benefit",

author = "Kantarjian, {Hagop M.} and Shilpa Paul",

year = "2018",

month = apr,

day = "15",

doi = "10.1002/cncr.31292",

language = "English (US)",

volume = "124",

pages = "1644--1646",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "8",

}

TY - JOUR

T1 - Hepatitis C

T2 - When high drug prices preclude patient benefit

AU - Kantarjian, Hagop M.

AU - Paul, Shilpa

PY - 2018/4/15

Y1 - 2018/4/15

UR - http://www.scopus.com/inward/record.url?scp=85045130855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045130855&partnerID=8YFLogxK

U2 - 10.1002/cncr.31292

DO - 10.1002/cncr.31292

M3 - Comment/debate

C2 - 29486061

AN - SCOPUS:85045130855

SN - 0008-543X

VL - 124

SP - 1644

EP - 1646

JO - Cancer

JF - Cancer

IS - 8

ER -

Hepatitis C: When high drug prices preclude patient benefit

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this